Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| ZEVRA THERAPEUTICS, INC.ZVRA · Entity 5212 | Director | April 25, 2023 | May 09, 2023 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
ZEVRA THERAPEUTICS, INC.
Report date April 25, 2023 · Filed May 09, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.59 · Expires 2033-04-24 | Direct | 49,200 |
Reported balance
After 2023-04-25 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2023-04-25 · Grant · Acquired 49,200 · Balance 49,200 F1: The exercise price is equal to the closing price of the Issuer's common stock on the Nasdaq Global Select Market on the date of grant, April 25, 2023. F2: This grant was awarded as compensation for the Reporting Person's service on the Issuer's board of directors pursuant to the Issuer's eighth amended and restated non-employee director compensation policy. F3: One hundred percent (100%) of the shares subject to the option shall vest on the earlier of (i) the first anniversary of the date of grant, (ii) one day prior to the date of the first annual meeting of the Issuer's stockholders following the date of grant or (iii) immediately prior to a change in control of the Issuer, subject in each case to the Reporting Person's continued service on such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The exercise price is equal to the closing price of the Issuer's common stock on the Nasdaq Global Select Market on the date of grant, April 25, 2023.
F2: This grant was awarded as compensation for the Reporting Person's service on the Issuer's board of directors pursuant to the Issuer's eighth amended and restated non-employee director compensation policy.
F3: One hundred percent (100%) of the shares subject to the option shall vest on the earlier of (i) the first anniversary of the date of grant, (ii) one day prior to the date of the first annual meeting of the Issuer's stockholders following the date of grant or (iii) immediately prior to a change in control of the Issuer, subject in each case to the Reporting Person's continued service on such vesting date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| April 25, 2023 Filed May 9, 2023 01:53 UTC | ZEVRA THERAPEUTICS, INC. ZVRA · Entity 5212 | GrantStock Option (right to buy) · Derivative | 49,200 | $0.00 Strike: $5.59 | $0.00 |
DisclosureSEC source: 0001437749-23-013125 · rdgdoc.xml · derivative · entry 1 Plooster Matthew R · CIK 0001638364 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 49,200 Underlying: Common Stock · 49,200 shares Expires 2033-04-24 F1 · derivative.exercise_price: The exercise price is equal to the closing price of the Issuer's common stock on the Nasdaq Global Select Market on the date of grant, April 25, 2023. F2 · shares: This grant was awarded as compensation for the Reporting Person's service on the Issuer's board of directors pursuant to the Issuer's eighth amended and restated non-employee director compensation policy. F3 · derivative.exercise_date: One hundred percent (100%) of the shares subject to the option shall vest on the earlier of (i) the first anniversary of the date of grant, (ii) one day prior to the date of the first annual meeting of the Issuer's stockholders following the date of grant or (iii) immediately prior to a change in control of the Issuer, subject in each case to the Reporting Person's continued service on such vesting date. Read SEC document |
| March 09, 2023 Filed Mar 13, 2023 11:59 UTC | ZEVRA THERAPEUTICS, INC. ZVRA · Entity 5212 | PurchaseCommon Stock | 11,000 | $4.20 | $46,148.30 |
DisclosureSEC source: 0001437749-23-006280 · rdgdoc.xml · nonDerivative · entry 1 Plooster Matthew R · CIK 0001638364 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,500 F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.1166 to $4.26, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F1 · ownership.direct: Held jointly with spouse. Read SEC document |
| June 28, 2022 Filed Jun 30, 2022 21:19 UTC | ZEVRA THERAPEUTICS, INC. KMPH · Entity 5212 | GrantStock Option (right to buy) · Derivative | 15,000 | $0.00 Strike: $4.52 | $0.00 |
DisclosureSEC source: 0001437749-22-016301 · rdgdoc.xml · derivative · entry 1 Plooster Matthew R · CIK 0001638364 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2032-06-27 F1 · derivative.exercise_price: The exercise price is equal to the closing price of the Issuer's common stock on the Nasdaq Global Select Market on the date of grant, June 28, 2022. F2 · shares: This grant was awarded as compensation for the Reporting Person's service on the Issuer's board of directors pursuant to the Issuer's seventh amended and restated non-employee director compensation policy. F3 · derivative.exercise_date: One hundred percent (100%) of the shares subject to the option shall vest on the earlier of (i) the first anniversary of the date of grant, (ii) one day prior to the date of the first annual meeting of the Issuer's stockholders following the date of grant or (iii) immediately prior to a change in control of the Issuer, subject in each case to the Reporting Person's continued service on such vesting date. Read SEC document |
| May 18, 2022 Filed May 18, 2022 23:01 UTC | ZEVRA THERAPEUTICS, INC. KMPH · Entity 5212 | PurchaseCommon Stock | 339 | $4.97 | $1,684.83 |
DisclosureSEC source: 0001437749-22-012945 · rdgdoc.xml · nonDerivative · entry 4 Plooster Matthew R · CIK 0001638364 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,500 F1 · ownership.direct: Held jointly with spouse. Read SEC document |
| May 18, 2022 Filed May 18, 2022 23:01 UTC | ZEVRA THERAPEUTICS, INC. KMPH · Entity 5212 | PurchaseCommon Stock | 3,051 | $4.96 | $15,132.96 |
DisclosureSEC source: 0001437749-22-012945 · rdgdoc.xml · nonDerivative · entry 3 Plooster Matthew R · CIK 0001638364 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,161 F1 · ownership.direct: Held jointly with spouse. Read SEC document |
| May 18, 2022 Filed May 18, 2022 23:01 UTC | ZEVRA THERAPEUTICS, INC. KMPH · Entity 5212 | PurchaseCommon Stock | 915 | $4.95 | $4,529.25 |
DisclosureSEC source: 0001437749-22-012945 · rdgdoc.xml · nonDerivative · entry 2 Plooster Matthew R · CIK 0001638364 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,110 F1 · ownership.direct: Held jointly with spouse. Read SEC document |
| May 18, 2022 Filed May 18, 2022 23:01 UTC | ZEVRA THERAPEUTICS, INC. KMPH · Entity 5212 | PurchaseCommon Stock | 695 | $4.94 | $3,433.30 |
DisclosureSEC source: 0001437749-22-012945 · rdgdoc.xml · nonDerivative · entry 1 Plooster Matthew R · CIK 0001638364 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,195 F1 · ownership.direct: Held jointly with spouse. Read SEC document |
| December 01, 2021 Filed Dec 1, 2021 21:28 UTC | ZEVRA THERAPEUTICS, INC. KMPH · Entity 5212 | GrantCommon Stock | 2,500 | $8.44 | $21,100.00 |
DisclosureSEC source: 0001437749-21-027630 · rdgdoc.xml · nonDerivative · entry 1 Plooster Matthew R · CIK 0001638364 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,500 F1 · ownership.direct: Held jointly with spouse. Read SEC document |
| June 17, 2021 Filed Jun 21, 2021 12:35 UTC | ZEVRA THERAPEUTICS, INC. KMPH · Entity 5212 | GrantStock Option (right to buy) · Derivative | 15,000 | $0.00 Strike: $15.47 | $0.00 |
DisclosureSEC source: 0001437749-21-015181 · rdgdoc.xml · derivative · entry 1 Plooster Matthew R · CIK 0001638364 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2031-06-16 F1 · derivative.exercise_price: The exercise price is equal to the closing price of the Issuer's common stock on the Nasdaq Capital Market on the date of grant, June 17, 2021. F2 · shares: This grant was awarded as compensation for the Reporting Person's service on the Issuer's board of directors pursuant to the Issuer's sixth amended and restated non-employee director compensation policy. F3 · derivative.exercise_date: One hundred percent (100%) of the shares subject to the option shall vest on the earlier of (i) the first anniversary of the date of grant, (ii) one day prior to the date of the first annual meeting of the Issuer's stockholders following the date of grant or (iii) immediately prior to a change in control of the Issuer, subject in each case to the Reporting Person's continued service on such vesting date. Read SEC document |
| June 19, 2020 Filed Jun 23, 2020 00:43 UTC | ZEVRA THERAPEUTICS, INC. KMPH · Entity 5212 | GrantStock Option (right to buy) · Derivative | 30,000 | $0.00 Strike: $0.27 | $0.00 |
DisclosureSEC source: 0001437749-20-013589 · rdgdoc.xml · derivative · entry 1 Plooster Matthew R · CIK 0001638364 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 30,000 shares Expires 2030-06-18 F1 · derivative.exercise_price: The exercise price is equal to the closing price of the Issuer's common stock on the OTCQB Venture Market on the date of grant, June 19, 2020. F2 · shares: This grant was awarded as compensation for the Reporting Person's service on the Issuer's board of directors pursuant to the Issuer's fourth amended and restated non-employee director compensation policy. F3 · derivative.exercise_date: One hundred percent (100%) of the shares subject to the option shall vest on the earlier of (i) the first anniversary of the date of grant, (ii) one day prior to the date of the first annual meeting of the Issuer's stockholders following the date of grant or (iii) immediately prior to a change in control of the Issuer, subject in each case to the Reporting Person's continued service on such vesting date. Read SEC document |
| June 30, 2019 Filed Jul 2, 2019 21:03 UTC | ZEVRA THERAPEUTICS, INC. KMPH · Entity 5212 | GrantCommon Stock | 7,857 | $0.00 | $0.00 |
DisclosureSEC source: 0001437749-19-013391 · rdgdoc.xml · nonDerivative · entry 1 Plooster Matthew R · CIK 0001638364 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,512 F1 · shares: Grant to the Reporting Person of a fully vested restricted stock award ("RSA") under the Issuer's 2014 Equity Incentive Plan. The RSA was granted to the Reporting Person in lieu of the quarterly cash compensation payable to the Reporting Person pursuant to the Issuer's Third Amended and Restated Non-Employee Director Compensation Policy. Read SEC document |
| May 10, 2019 Filed May 15, 2019 00:38 UTC | ZEVRA THERAPEUTICS, INC. KMPH · Entity 5212 | GrantCommon Stock | 8,487 | $0.00 | $0.00 |
DisclosureSEC source: 0001437749-19-009880 · rdgdoc.xml · nonDerivative · entry 1 Plooster Matthew R · CIK 0001638364 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,655 F1 · shares: Grant to the Reporting Person of a fully vested restricted stock award ("RSA") under the Issuer's 2014 Equity Incentive Plan. The RSA was granted to the Reporting Person in lieu of the quarterly cash compensation payable to the Reporting Person pursuant to the Issuer's Third Amended and Restated Non-Employee Director Compensation Policy. Read SEC document |
| April 24, 2019 Filed Apr 26, 2019 21:01 UTC | ZEVRA THERAPEUTICS, INC. KMPH · Entity 5212 | GrantStock Option (right to buy) · Derivative | 30,000 | $0.00 Strike: $1.62 | $0.00 |
DisclosureSEC source: 0001437749-19-008064 · rdgdoc.xml · derivative · entry 1 Plooster Matthew R · CIK 0001638364 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 30,000 shares Expires 2029-04-23 F1 · derivative.exercise_price: The exercise price is equal to the closing price of the Issuer's common stock on the Nasdaq Global Market on the date of grant, April 24, 2019. F2 · shares: This grant was awarded as compensation for the Reporting Person's service on the Issuer's board of directors pursuant to the Issuer's third amended and restated non-employee director compensation policy. F3 · derivative.exercise_date: One hundred percent (100%) of the shares subject to the option shall vest on the earlier of (i) the first anniversary of the date of grant, (ii) one day prior to the date of the first annual meeting of the Issuer's stockholders following the date of grant or (iii) immediately prior to a change in control of the Issuer, subject in each case to the Reporting Person's continued service on such vesting date. Read SEC document |
| May 22, 2018 Filed May 24, 2018 20:04 UTC | ZEVRA THERAPEUTICS, INC. KMPH · Entity 5212 | GrantStock Option (right to buy) · Derivative | 15,000 | $0.00 Strike: $6.10 | $0.00 |
DisclosureSEC source: 0001437749-18-010651 · rdgdoc.xml · derivative · entry 1 Plooster Matthew R · CIK 0001638364 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2028-05-21 F1 · derivative.exercise_price: The exercise price is equal to the closing price of the Issuer's common stock on the Nasdaq Global Market on the date of grant, May 22, 2018. F2 · shares: This grant was awarded as compensation for the Reporting Person's service on the Issuer's board of directors pursuant to the Issuer's non-employee director compensation policy. F3 · derivative.exercise_date: One hundred percent (100%) of the shares subject to the option shall vest on the earlier of (i) the first anniversary of the date of grant, (ii) one day prior to the date of the first annual meeting of the Issuer's stockholders following the date of grant or (iii) immediately prior to a change in control of the Issuer, subject in each case to the Reporting Person's continued service on such vesting date. Read SEC document |
| May 23, 2017 Filed May 24, 2017 21:30 UTC | ZEVRA THERAPEUTICS, INC. KMPH · Entity 5212 | GrantStock Option (right to buy) · Derivative | 10,000 | $0.00 Strike: $3.95 | $0.00 |
DisclosureSEC source: 0001437749-17-010009 · rdgdoc.xml · derivative · entry 1 Plooster Matthew R · CIK 0001638364 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2027-05-22 F1 · derivative.exercise_price: The exercise price is equal to the closing price of the Issuer's common stock on the Nasdaq Global Market on the date of grant, May 23, 2017. F2 · shares: This grant was awarded as compensation for the Reporting Person's service on the Issuer's board of directors pursuant to the Issuer's non-employee director compensation policy. F3 · derivative.exercise_date: One hundred percent (100%) of the shares subject to the option shall vest on the earlier of (i) the first anniversary of the date of grant, (ii) one day prior to the date of the first annual meeting of the Issuer's stockholders following the date of grant or (iii) immediately prior to a change in control of the Issuer, subject in each case to the Reporting Person's continued service on such vesting date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.